Zimmer Biomet (NYSE:ZBH) Insider Chad Phipps Sells 3,000 Shares

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) insider Chad Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider directly owned 65,231 shares of the company’s stock, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zimmer Biomet Stock Up 0.6%

NYSE ZBH traded up $0.56 on Wednesday, reaching $94.78. The company had a trading volume of 1,994,494 shares, compared to its average volume of 2,265,184. The company’s fifty day moving average is $95.12 and its 200-day moving average is $91.59. The firm has a market capitalization of $18.08 billion, a price-to-earnings ratio of 23.06, a price-to-earnings-growth ratio of 1.85 and a beta of 0.47. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $106.88.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter last year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s payout ratio is presently 23.36%.

Institutional Trading of Zimmer Biomet

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZBH. DV Equities LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $25,000. Tacita Capital Inc bought a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $26,000. Ancora Advisors LLC acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $29,000. Monetary Solutions Ltd bought a new stake in Zimmer Biomet in the 4th quarter valued at $30,000. Finally, Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet during the 4th quarter valued at $31,000. 88.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ZBH. Citigroup lowered their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Sanford C. Bernstein boosted their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. BMO Capital Markets restated a “market perform” rating and set a $96.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Canaccord Genuity Group raised their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Finally, Truist Financial lifted their target price on Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.